

## STUDY PROTOCOL

University of Florida  
College of Medicine  
Health Science Center  
1600 SW Archer Road  
Gainesville, Florida 32610  
Phone: 001-3523954680 X85955  
Fax: 001-352-Wi-EtO83

Knoll AG  
Research and Development  
Clinical Cardiology  
P O Box 21 08 05  
D-67008 Ludwigshafen  
Phone: 0049 621 589-1906  
Fax: 0049 621 589 1900

December 2, 1997 version  
Up to and including October 7, 1998 revisions

The - **IN**ternational - **VE**rapamil **SRI** Trandolapril - Study **INVEST**

## INVEST

INVEST is a randomized controlled clinical trial comparing a calcium antagonist treatment strategy (Isoptin" SR) with a non calcium antagonist treatment strategy for the control of hypertension in a primary care coronary artery disease patient population.

## INVEST STUDY

**Principal Investigator:**

Name: Professor Carl J. Pepine  
Institution: University of Florida  
Address: College of Medicine  
Gainesville  
Florida  
Phone: 001 -352-84M620  
Fax: 001 -352-371 -0370

**Co-Investigator**

Jonathan N. Tobin, Ph.D.  
Clinical Directors Network, Inc. (CDN)  
5 West 37 th Street , 10 th Floor  
New York , NY 10018  
TEL: (212) 382-0699, ext. 234  
FAX: (212) 382-0669  
E-MAIL: jntobin@CDNetwork.org  
www.CDNetwork.org

**Clinical project consultant:**

Name: Dr. Peter Zilles  
Institution: Knoll AG  
Address: Knollstr. 50  
67061 Ludwigshafen  
Germany  
Phone: 0049-621-5851 906  
Fax: 0049-621 -589-1 900

**Project Director:**

Andrea Cassells , MPH  
Clinical Directors Network, Inc.  
5 West 37 th Street , 10 th Floor  
New York , N. Y. 10018  
TEL: (212) 382-0699 ext.227  
FAX: (212) 382-0669  
EMAIL: acass@CDNetwork.org  
www.CDNetwork.org

**Biometricians:**

Name: Prof Ronald Marks	Prof Michael Conlon	Dr. Peter Volkers
Institution: University of Florida	University of Florida	Knoll AG
Address: Department of Statistics Gainesville Florida	Department of Statistics Gainesville Florida	Knollstr. 50 67061 Ludwigshafen Germany
Phone: 001 -352-392-8446	001 -352-392-8446	0049421 -5851 934
Fax: 001 -352-39241 68	001 -352-39241 68	0049-621-589-1 925

**Study coordination:**

Name: Dr. Eileen Handberg-  
Thurmond  
Institution: University of Florida  
Div. of Cardiovas.Medicine  
Address: Clinical Trials Section  
Gainesville  
Florida  
Phone: 001 -352-046-0610  
Fax: 001-352-371 -0370

**Pharmacy coordinating center:**

Dr. Rhonda CooperdeHoff  
University of Florida  
Clinical Trials Section  
Gainesville  
Florida  
001 -352-395-0680 X52986  
001 -352-395.6937

**Administration and technical support:**

Name: H. Robert Kolb, R.N.  
Institution: University of Florida  
Address: Clinical Trials section  
Gainesville  
Florida  
Phone: 001-888-214-21 67  
Fax: 001-888-214-2169

**INVEST** is a randomized controlled clinical trial comparing a calcium antagonist treatment strategy (Isoptine SR) with a non calcium antagonist treatment strategy for the control of hypertension in a primary care coronary artery disease patient population.

## **EXECUTIVE SUMMARY**

INVEST is an investigator initiated international, prospective, randomized study comparing two pharmacotherapy strategies to control hypertension in ambulatory patients with coronary artery disease (CAD). One strategy, the calcium antagonist care strategy, centers on a calcium antagonist (verapamil SR) followed by addition of an ACE inhibitor (trandolapril) and then diuretic (hydrochlorothiazide) as needed to achieve target blood pressures (BP). The other strategy, the noncalcium antagonist care strategy, uses a beta- blocker (atenolol) followed by addition of lowdose diuretic and then an ACE inhibitor (trandolapril) as needed to reach target BP. In either strategy additional drugs can be added provided the calcium antagonist is retained in the calcium antagonist care strategy and calcium antagonists are omitted in the non-calcium antagonist care strategy. The study is organized into 15 international regions with about 1,500 study investigators randomizing approximately 27,000 patients who will be treated for at least two years. The primary response variable is the occurrence of adverse outcome, defined as any of the following events: all cause mortality, nonfatal MI or nonfatal stroke. A number of secondary response variables will also be evaluated. Unique features of INVEST are, in addition to its size and international scope, its design to mimic standard clinical practice and its all electronic online data entry, drug distribution system, study management system, and electronic physician compensation. This system will permit the entire trial to be conducted via the Internet. This design is believed to be a forerunner of clinical trials research for the future.